Welcome!

News Feed Item

2013 Japanese Hospital Microbiology Testing Market

NEW YORK, Jan. 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

2013 Japanese Hospital Microbiology Testing Market

http://www.reportlinker.com/p01083065/2013-Japanese-Hospital-Microbiolog...

This new report from Venture Planning Group contains 891 pages, 75 tables, and presents a comprehensive analysis of the Japanese hospital microbiology testing market, including:

·         Major issues pertaining to the Japanese hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.

·         Current scientific views on definition, epidemiology, and etiology of major infectious diseases and microorganisms.

·         Volume and sales forecasts for 80 microbiology tests performed in Japanese hospital laboratories.

·         Instrumentation technologies and feature comparison of leading analyzers.

·         Sales and market shares of leading suppliers.

·         Emerging diagnostic technologies and their potential market applications.

·         Product development opportunities.

·         Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

·         Business opportunities and strategic recommendations for suppliers.

Contains 891 pages and 75 tables

 

 

 

Table of Contents

 

Introduction

Worldwide Market and Technology Overview

A. Major Infectious Disease Tests

1. AIDS

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

2. Adenovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

d. Adeno-Associated Viruses(AAV)

3. Aeromonas

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

4. Anthrax/Bacillus Anthracis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

5. Arboviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

6. Babesiosis

a. Background

7. Bacillary Epithelioid Angiomatosis (BEA)

And Other Bartonella (Rochalimaea)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

8. Blastocystis Hominis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

9. Brucella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

10. Campylobacter

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

11. Candida

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

12. Chagas Disease

a. Background

13. Chancroid

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

14. Chlamydia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

15. Clostridium Difficile

a. Background

b. Diagnostic Tests

c. Drugs and Vaccines

16. Coronaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

17. Coxsackieviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

18. Creutzfeldt-Jakob's Disease

a. Background

b. Diagnostic Tests

c. Vaccines

19. Cryptosporidium Parvum

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

20. Cyclospora Cayetanensis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

21. Cytomegalovirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

22. Ebola Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

23. E. Coli

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

24. EchoVirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

25. Encephalitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

26. Enteroviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

27. Epstein-Barr Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

28. Giardia Lamblia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

29. Gonorrhea

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

30. Granuloma Inguinale

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

31. Hantavirus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

32. Helicobacter Pylori

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

33. Hepatitis

a. Background

b. Hepatitis A

c. Hepatitis B

d. Hepatitis C

e. Vaccines and Drugs

34. Herpes Simplex Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

35. Human Herpes Virus-6 (HHV-6)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

36. Influenza Viruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

37. Legionella

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

38. Lyme Disease

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

39. Lymphogranuloma Venereum (LGV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

40. Malaria

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

41. Measles (Rubeola)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

42. Meningitis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

43. Microsporidium

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

44. Mononucleosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

45. Mumps

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

46. Mycoplasma

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

47. Papillomaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

48. Parvovirus B19

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

49. Pneumonia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

50. Polyomaviruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

51. Pseudomonas Aeruginosa

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

52. Rabies

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

53. Respiratory Syncytial Virus (RSV)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

54. RhinoViruses

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

55. RotaVirus (REOVIRUS)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

56. Rubella(MEASLES)

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

57. Salmonellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

58. Septicemia

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

59. Shigellosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

60. Staphylococcus Aureus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

61. Streptococci

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

62. Syphilis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

63. Toxoplasmosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

64. Trichomonas Vaginalis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

65. Tuberculosis

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

66. Vibrio

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

67. West Nile Virus

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

68. Yersina

a. Background

b. Diagnostic Tests

c. Vaccines and Drugs

B. Instrumentation Review of Leading Analyzers Marketed

by Abbott, Beckman Coulter/Danaher, BioMerieux,

Ortho-Clinical Diagnostics, Roche, Siemens, Tosoh,

Wallac and Other Suppliers

C. Emerging Diagnostic Technologies

1. Molecular Diagnostics

2. Monoclonal Antibodies

3. Immunoassays

4. Differential Light Scattering

5. Information Technology

6. Artificial Intelligence

7. Liposomes

8. Flow Cytometry

9. Chromatography

10. Diagnostic Imaging

11. Gel Microdroplets

12. Other

Japan

A. Executive Summary

B. Business Environment

C. Market Structure

D. Market Size, Growth and Major Suppliers

Major Product Development Opportunities

A. Instrumentation

B. Reagent Kits and Test Systems/Panels

C. Computers, Software and Automation

D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies for Decentralized

Testing Markets

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation

Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

Competitive Assessments

- Abbott

- Affymetrix

- Beckman Coulter/Danaher

- Becton Dickinson

- bioMerieux

- Bio-Rad

- Cepheid

- Diamedix

- DiaSorin

- Eiken Chemical

- Enzo Biochem

- Fujirebio

- Gen-Probe

- Hologic

- ID Biomedical

- Innogenetics/Solvay

- Kreatech

- Life Technology

- Lonza

- Nanogen/Elitech

- Novartis Diagnostics

- Ortho-Clinical Diagnostics

- Qiagen

- Roche

- Scienion

- Sequenom

- SeraCare

- Siemens

- Takara Bio

- Thermo Fisher

- Wallac

- Wako

 

 

 

List of Tables

 

Major Companies Developing or Marketing AIDS Tests

Major Companies Developing or Marketing Adenovirus

Tests

Major Companies Developing or Marketing Bartonella

Tests

Major Companies Developing or Marketing

Campylobacter Tests

Major Companies Developing or Marketing Candida

Tests

Major Companies Developing or Marketing Chlamydia

Tests

Major Companies Developing or Marketing Clostridium

Tests

Major Companies Developing or Marketing Coronavirus

Tests

Major Companies Developing or Marketing Cryptosporidium

Tests

Major Companies Developing or Marketing CMV Tests

Major Companies Developing or Marketing Echovirus

Tests

Major Companies Developing or Marketing Enterovirus

Tests

Major Companies Developing or Marketing EBV Tests

Major Companies Developing or Marketing Giardia

Tests

Major Companies Developing or Marketing Gonorrhea

Tests

Major Companies Developing or Marketing Hantavirus

Tests

Major Companies Developing or Marketing Helicobacter

Pylori Tests

Major Companies Developing or Marketing Hepatitis

Tests

Major Companies Developing or Marketing Herpes

Tests

Major Companies Developing or Marketing Influenza

Tests

Major Companies Developing or Marketing Legionella

Tests

Major Companies Developing or Marketing Lyme Disease

Tests

Major Companies Developing or Marketing Lymphogranuloma

Tests

Major Companies Developing or Marketing Malaria

Tests

Major Companies Developing or Marketing Measles

Tests

Major Companies Developing or Marketing Meningitis

Tests

Major Companies Developing or Marketing Microsporidium

Tests

Major Companies Developing or Marketing

Mononucleosis Tests

Major Companies Developing or Marketing Mumps Tests

Major Companies Developing or Marketing Mycoplasma

Tests

Major Companies Developing or Marketing Papilloma

Virus Tests

Major Companies Developing or Marketing Parvovirus

Tests

Major Companies Developing or Marketing Pneumonia

Tests

Major Companies Developing or Marketing RSV Tests

Major Companies Developing or Marketing Rotavirus

Tests

Major Companies Developing or Marketing Rubella

Tests

Major Companies Developing or Marketing Salmonella

Tests

Major Companies Developing or Marketing Septicemia

Tests

Major Companies Developing or Marketing Shigella

Tests

Major Companies Developing or Marketing Staphylococci

Tests

Major Companies Developing or Marketing

Streptococci Tests

Major Companies Developing or Marketing Syphilis

Tests

Major Companies Developing or Marketing Toxoplasmosis

Tests

Major Companies Developing or Marketing Trichomonas

Tests

Major Companies Developing or Marketing Tuberculosis

Tests

Major Companies Developing or Marketing West Nile

Tests

Major Companies Developing or Marketing Yersinia Tests

Japan Summary Table

All Infectious Diseases Test Volume and Diagnostics

Sales Forecast by Market Segment

Japan

Hospital Laboratories Performing Infectious Disease

Tests by Bed Size

Japan

Hospital Laboratories Infectious Disease Test

Volume Forecast

Japan

Hospital Laboratories Infectious Disease Diagnostics

Market Forecast

Japan

AIDS Testing Market Diagnostics Sales

by Major Supplier

Japan

Campylobacter Testing Market Diagnostics Sales

by Major Supplier

Japan

Candida Testing Market Diagnostics Sales

by Major Supplier

Japan

Chlamydia Testing Market Diagnostics Sales

by Major Supplier

Japan

CMV Testing Market Diagnostics Sales

by Major Supplier

Japan

Gonorrhea Testing Market Diagnostics Sales

by Major Supplier

Japan

Hepatitis Testing Market Diagnostics Sales

by Major Supplier

Japan

Hepatitis C Testing Market Diagnostics Sales

by Major Supplier

Japan

Herpes Testing Market Diagnostics Sales

by Major Supplier

Japan

Legionella Testing Market Diagnostics Sales Forecast

by Major Supplier

Japan

Meningitis Testing Market Diagnostics Sales

by Major Supplier

Japan

Mononucleosis Testing Market Diagnostics Sales

by Major Supplier

Japan

Mycoplasma Testing Market Diagnostics Sales

by Major Supplier

Japan

Pneumonia Testing Market Diagnostics Sales

by Major Supplier

Japan

RSV Testing Market Diagnostics Sales by Major Supplier

Japan

Rotavirus Testing Market Diagnostics Sales

by Major Supplier

Japan

Rubella Testing Market Diagnostics Sales

by Major Supplier

Japan

Septicemia Testing Market Diagnostics Sales

by Major Supplier

Japan

Shigella Testing Market Diagnostics Sales

by Major Supplier

Japan

Streptococci Testing Market Diagnostics Sales

by Major Supplier

Japan

Syphilis Testing Market Diagnostics Sales

by Major Supplier

Japan

Toxoplasmosis Testing Market Diagnostics Sales

by Major Supplier

Japan

Trichomonas Testing Market Diagnostics Sales

by Major Supplier

Japan

Tuberculosis Testing Market Diagnostics Sales

by Major Supplier

 

 

 

To order this report:

In_Vitro_Diagnostic Industry: 2013 Japanese Hospital Microbiology Testing Market

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his Day 2 Keynote at @ThingsExpo, Henrik Kenani Dahlgren, Portfolio Marketing Manager at Ericsson, discussed how to plan to cooperate, partner, and form lasting all-star teams to change the...
"I think that everyone recognizes that for IoT to really realize its full potential and value that it is about creating ecosystems and marketplaces and that no single vendor is able to support what is required," explained Esmeralda Swartz, VP, Marketing Enterprise and Cloud at Ericsson, in this SYS-CON.tv interview at @ThingsExpo, held June 7-9, 2016, at the Javits Center in New York City, NY.
When building large, cloud-based applications that operate at a high scale, it’s important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. “Fly two mistakes high” is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Lee A...
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at 20th Cloud Expo, Ed Featherston, director/senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet and...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
910Telecom exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and exchanges.
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
As software becomes more and more complex, we, as software developers, have been splitting up our code into smaller and smaller components. This is also true for the environment in which we run our code: going from bare metal, to VMs to the modern-day Cloud Native world of containers, schedulers and micro services. While we have figured out how to run containerized applications in the cloud using schedulers, we've yet to come up with a good solution to bridge the gap between getting your contain...
The modern software development landscape consists of best practices and tools that allow teams to deliver software in a near-continuous manner. By adopting a culture of automation, measurement and sharing, the time to ship code has been greatly reduced, allowing for shorter release cycles and quicker feedback from customers and users. Still, with all of these tools and methods, how can teams stay on top of what is taking place across their infrastructure and codebase? Hopping between services a...
Niagara Networks exhibited at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.